ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS

/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and...

Related Keywords

New York ,United States ,California ,Canada ,Dublin ,Ireland ,Chestnut Ridge ,Irvine ,Canadian ,Blaise Coleman ,Company Net ,Branded Pharmaceuticals ,Company Net Debt Leverage Ratio ,Linkedin ,Generic Pharmaceuticals ,Endo Investor Relations Department ,Nasdaq ,Exchange Commission ,International Pharmaceuticals ,Pfizer Inc ,Endo International ,Company Loss ,Chief Executive Officer ,Months Ended December ,Ended December ,Diluted Net ,Continuing Operations ,Diluted Weighted Average Shares ,Diluted Net Income ,Adjusted Diluted Weighted Average Shares ,Adjusted Income ,Sterile Injectables ,Specialty Products ,Note Regarding Forward Looking Statements ,Operating Expenses ,Total Revenues ,Nasal Spray ,Condensed Consolidated Statement ,Condensed Consolidated Balance Sheet ,Cash Flow ,Qualified Settlement ,Current Report ,Supplemental Financial Information ,Consolidated Statements ,Net Debt Leverage Ratio ,Net Debt ,Restricted Cash ,Net Debt Leverage ,Debt Leverage Ratio ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Endo International Plc ,